Abstract Introduction: human papillomavirus (HPV) is the most common sexually transmitted disease (STD) throughout the world. The incidence of HPV has been increasing over recent years. Since scant information has been reported on the prevalence of HPV and its related risk factors in Yazd province, the present study aimed to evaluate effects of demographic characteristics as well as the risk...

BACKGROUND Cervical cancer is currently the leading cause of cancer mortality among women in South Vietnam and the second leading cause of cancer mortality in North Vietnam. Human papillomavirus (HPV) vaccination has the potential to substantially decrease this burden. The World Health Organization (WHO) recommends that a cost-effectiveness analysis of HPV vaccination is conducted before nation...

The discovery of human papillomavirus (HPV) as a necessary etiological factor for cervical cancer has spurred the development of preventive and therapeutic HPV vaccines for the control of HPV-associated malignancies including cervical, vulvar, vaginal, and a subset of head and neck cancers. The commercial preventive HPV vaccines, Gardasil and Cervarix, use HPV virus-like particles to generate n...

BACKGROUND In 2007, Australia implemented the National human papillomavirus (HPV) Vaccination Program, which provides quadrivalent HPV vaccine free to all women aged 12-26 years. Following notification of 7 presumptive cases of anaphylaxis in the state of New South Wales, Australia, we verified cases and compared the incidence of anaphylaxis following HPV vaccination to other vaccines in compar...

© 2007, AWHONN 133 Worldwide, cervical cancer is the second most common cancer in women (CDC, 2006). The ACS (2006) estimates that more than 9,700 cases of invasive cervical cancer will be diagnosed this year in the United States. During 2006 alone, approximately 3,700 U.S. women will have died from this form of cancer (ACS). The rate of cervical cancer deaths in the United States has dropped t...

Cervical cancer screening has reduced the incidence of cervical cancer over the past 75 years. The primary aim of this study was to determine if women receiving Gardasil™ (HPV4 vaccine) participated in future cervical cancer screening at the same rate as that observed for unvaccinated women matched on birth year and health care campus. This is a retrospective cohort study of subjects selected f...

During its February 2015 meeting, the Advisory Committee on Immunization Practices (ACIP) recommended 9-valent human papillomavirus (HPV) vaccine (9vHPV) (Gardasil 9, Merck and Co., Inc.) as one of three HPV vaccines that can be used for routine vaccination. HPV vaccine is recommended for routine vaccination at age 11 or 12 years. ACIP also recommends vaccination for females aged 13 through 26 ...

The family of human papillomaviruses (HPVs) includes more than 130 genotypes, many of which infect the genital tract, and these can be classified as low risk or high risk for induction of genital neoplasia. Two prophylactic vaccines are currently available for the prevention of genital HPV infection: a quadrivalent (Gardasil); Merck & Co. Inc) and a bivalent (Cervarix; GlaxoSmithKline) vaccine....

INTRODUCTION The quadrivalent vaccine that protects against human papilloma virus types 6, 11, 16 and 18 (Q-HPV vaccine, Gardasil) was included into the Danish childhood vaccination programme in 2009. During the past years, a collection of symptoms primarily consistent with sympathetic nervous system dysfunction have been described as suspected side effects to the Q-HPV vaccine. METHODS We pr...

Human papilloma virus (HPV)-associated head and neck carcinoma is quite heterogeneous and most of the tumors arise in the oral cavity, oropharynx, hypopharynx and larynx. HPV was just recently recognized as an emerging risk factor for oropharyngeal squamous cell carcinoma (OSCC). HPV(+) tumors represent 5-20% of all head and neck squamous-cell carcinomas (HNSCCs) and 40-90% of those arising fro...